way HW, Spencer RGS, Greig NH, EganJM: Exendin-4 decelerates food intake,weight gain, and fat deposition in Zuckerrats. Endocrinology 141:1936–1941, 2000 25. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, ParkesD, Young AA: Exenatide (exendin-4) im-proves insulin sensitivity and /H9252-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and bodyweight. Endocrinology 146:2069–2076, 2005 26. Declaration of Helsinski: Recommenda- tions guiding medical physicians in bio-medical research involving humansubjects. JAMA 277:925–926, 1997 27. Fineman MS, Shen LZ, Kristin Taylor T, Kim DD, Baron AD: Effectiveness of pro-gressive dose-escalation of exenatide (ex-endin-4) in reducing dose-limiting side-effects in subjects with type 2 diabetes.Diabetes Metab Res Rev 20:411–417, 2004 28. Neter J, Wasserman W, Kutner MH:Applied Linear Statistical Models. 3rd ed. Momewood, IL, Irwin, 1990 29. Milliken GA, Johnson DE: Analyses of